- Particular assembly of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed enterprise mixture of Larkspur with ZyVersa
- ZyVersa is a medical stage biopharmaceutical firm with two licensed proprietary product platforms, a ldl cholesterol efflux mediator concentrating on a number of renal ailments, and an inflammatory ASC inhibitor concentrating on quite a few inflammatory ailments
- ZyVersa and Larkspur Well being entered right into a definitive enterprise mixture settlement dated July 20, 2022, as amended (the “Enterprise Mixture Settlement”)
- Mixed firm anticipated to be named ZyVersa Therapeutics, Inc. and listed on NASDAQ in fourth quarter of 2022 beneath ticker “ZVSA”
BRIDGEWATER, N.J. and WESTON, Fla., Nov. 15, 2022 /PRNewswire/ — Larkspur Well being Acquisition Corp. (NASDAQ: LSPR or “Larkspur”), a blank-check particular objective acquisition firm, and ZyVersa Therapeutics, Inc. (“ZyVersa”), a medical stage specialty biopharmaceutical firm leveraging superior, proprietary applied sciences to develop product candidates that deal with unmet medical wants within the areas of renal and inflammatory ailments, are happy to announce that Larkspur’s proxy/registration assertion on Kind S-4 filed with the U.S. Securities and Trade Fee (“SEC”) on August 12, 2022, as amended (the “Registration Assertion”), was declared efficient by the SEC on November 14, 2022. The Registration Assertion was filed in reference to the proposed enterprise mixture between Larkspur and ZyVersa beforehand introduced on July 20, 2022.
Larkspur has scheduled a particular assembly of their stockholders to hunt approval and adoption of the Enterprise Mixture Settlement and the transactions contemplated thereby (the “Transaction”), and different associated issues, a key milestone within the enterprise mixture course of.
The Larkspur particular assembly of stockholders might be held on December 8, 2022, at 10:00 am Jap Time at https://www.cstproxy.com/lsprhealth/2022. Larkspur’s frequent stockholders of file as of the shut of enterprise on November 8, 2022, are entitled to obtain discover of, to vote, and have their votes counted on the particular assembly and any adjournment thereof. Larkspur’s stockholders might be mailed the proxy assertion and prospectus in reference to the Transaction starting November 14, 2022. The Registration Assertion containing the proxy assertion and prospectus incorporates necessary details about the proposed Transaction, the Enterprise Mixture Settlement, and the proposals to be thought-about on the particular assembly. The Registration Assertion containing the proxy assertion, prospectus, and proposals to be thought-about is offered by way of the SEC’s web site at www.sec.gov or at www.lsprhealth.com.
“We’re delighted to companion with ZyVersa on this enterprise mixture,” mentioned Daniel J. O’Connor, Chairman and Chief Govt Officer of Larkspur. “We imagine that ZyVersa has potential to construct stockholder worth, based mostly on its distinctive worth proposition summarized beneath,” continued Mr. O’Connor.
- Two proprietary drug platforms to deal with vital unmet wants of sufferers with renal ailments (VAR 200) and inflammatory ailments (IC 100)
- A section 2a-ready lead renal product candidate, VAR 200, which mediates removing of extra intracellular lipids that contribute to kidney harm resulting in end-stage renal illness
- A lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), which blocks initiation and perpetuation of damaging irritation that is pathogenic in a large number of inflammatory ailments
- An skilled CEO, Mr. Stephen Glover, who has co-founded and led a number of biopharma corporations
- A Administration workforce with deep scientific, industrial, and operational expertise
The closing of the Transaction, which is predicted to happen within the fourth quarter of 2022, is topic to approval by Larkspur’s stockholders and the opposite closing circumstances set forth within the definitive Enterprise Mixture Settlement. Upon closing of the Transaction, Larkspur is predicted to be renamed ZyVersa Therapeutics, Inc., and can proceed to function beneath the ZyVersa administration workforce, led by Stephen C. Glover, Co-Founder, Chief Govt Officer, and Chairman of ZyVersa. The mixed firm’s frequent inventory is anticipated to be listed on NASDAQ beneath ticker image “ZVSA.”
About Larkspur Well being Acquisition Corp.
Larkspur is a Particular Function Acquisition Firm (SPAC) shaped to determine a biopharmaceutical firm that may develop and thrive as a newly shaped public firm, and profit from Larkspur’s operational experience and a major infusion of capital. Every of Larkspur’s administration workforce and board of administrators have been former administration and govt management of personal and public biopharmaceutical corporations and have over 50+ years of mixture funding and operational experiences. The workforce strongly believes within the development alternatives within the biotechnology trade. They’re skilled operators who search to companion with prime innovators and thinkers within the biopharmaceutical subject. Their entrepreneurial strategy helps administration groups in making impactful choices with a watch towards development and operational excellence. For extra data, please go to www.lsprhealth.com.
About ZyVersa Therapeutics, Inc.
ZyVersa is a medical stage specialty biopharmaceutical firm leveraging superior, proprietary applied sciences to develop product candidates that deal with unmet medical wants within the areas of renal and inflammatory ailments. ZyVersa’s improvement pipeline contains section 2a prepared VAR 200, a ldl cholesterol efflux mediator for remedy of uncommon kidney illness, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to deal with different glomerular ailments, together with Alport syndrome and diabetic kidney illness. ZyVersa’s improvement pipeline additionally contains IC 100, a novel inflammasome ASC inhibitor being developed to deal with a large number of inflammatory ailments. For extra data, please go to www.zyversa.com.
Vital Data for Buyers and Stockholders and The place to Discover It
In reference to the transactions described herein, Larkspur filed its Registration Assertion on Kind S-4 that features a proxy assertion with respect to the stockholder assembly of Larkspur and a prospectus with respect to securities of the mixed firm. After the Registration Assertion is said efficient by the SEC, the proxy assertion/prospectus might be despatched to all Larkspur and ZyVersa stockholders. Larkspur may also file different paperwork concerning the proposed Enterprise Mixture with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITIES HOLDERS OF LARKSPUR AND ZYVERSA ARE URGED TO READ THE REGISTRATION STATEMENT, INCLUDING THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION AND THE PARTIES TO THE PROPOSED BUSINESS COMBINATION.
Buyers and securities holders will be capable to receive free copies of the Registration Assertion, proxy assertion/prospectus and all different related paperwork filed or that might be filed with the SEC by Larkspur by way of the web site maintained by the SEC at https://sec.gov/. As well as, the paperwork filed by Larkspur could also be obtained freed from cost from Larkspur’s web site at www.lsprhealth.com or by written request to [email protected]. Extra details about the proposed Transaction, together with a duplicate of the Enterprise Mixture Settlement and investor presentation, might be offered in a Present Report on Kind 8-Ok to be filed by Larkspur with the SEC which might be accessed at www.sec.gov in addition to on-line at www.lsprhealth.com.
Contributors within the Solicitation
Larkspur, ZyVersa, and their respective administrators and govt officers could also be deemed to be contributors within the solicitation of proxies from Larkspur’s stockholders in reference to the proposed Transaction. Details about Larkspur’s administrators and govt officers and their possession of Larkspur’s securities is ready forth in Larkspur’s Annual Report for the yr ended December 31, 2021, which was filed with the SEC on Kind 10-Ok, as modified or supplemented by any Kind 3 or Kind 4 filed with the SEC because the date of such submitting. Different data concerning the pursuits of the contributors within the proxy solicitation might be included within the proxy assertion/prospectus pertaining to the proposed Transactions when it turns into out there. These paperwork might be obtained freed from cost from the sources indicated above.
No Supply or Solicitation
This communication doesn’t represent a proposal to promote or the solicitation of a proposal to purchase any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction by which such supply, solicitation, or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of such different jurisdiction.
Ahead Wanting Statements
This press launch incorporates sure forward-looking statements inside the that means of the federal securities legal guidelines with respect to the proposed transaction between Larkspur Well being Acquisition Corp. (“Larkspur”), and ZyVersa Therapeutics, Inc. (“ZyVersa”). All statements apart from statements of historic information contained on this press launch, together with statements concerning Larkspur or ZyVersa’s future outcomes of operations and monetary place, the amount of money anticipated to be out there to ZyVersa after the closing and giving impact to any redemptions by Larkspur’s stockholders, ZyVersa’s enterprise technique, potential product candidates, product approvals, analysis and improvement prices, timing and chance of success, plans and aims of administration for future operations, future outcomes of present and anticipated product candidates, and anticipated use of proceeds, are forward-looking statements. These forward-looking statements usually are recognized by the phrases “imagine,” “undertaking,” “count on,” “anticipate,” “estimate,” “intend,” “technique,” “future,” “alternative,” “plan,” “might,” “ought to,” “will,” “would,” “might be,” “will proceed,” “will possible consequence,” and related expressions. These forward-looking statements are topic to quite a lot of dangers, uncertainties and assumptions, together with, however not restricted to, the next dangers referring to the proposed transaction: the incidence of any occasion, change or different circumstances that would give rise to the termination of the Enterprise Mixture Settlement; the danger that the transaction is probably not accomplished in a well timed method or in any respect, which can adversely have an effect on the worth of Larkspur’s securities; the incidence of any occasion, change or different circumstances that would give rise to the termination of the Enterprise Mixture Settlement; the lack to finish the Transactions, together with resulting from failure to acquire approval of the shareholders of Larkspur or different circumstances to closing within the Enterprise Mixture Settlement; the lack to acquire or preserve the itemizing of Larkspur’s frequent inventory on NASDAQ following the Transactions; the danger that the Transactions disrupt present plans and operations of ZyVersa because of the announcement and consummation of the Transactions; the flexibility to acknowledge the anticipated advantages of the Transactions, which can be affected by, amongst different issues, competitors, the flexibility of the mixed firm to develop and handle development economically and rent and retain key workers; the dangers that ZyVersa’s product candidates in improvement fail medical trials or aren’t permitted by the U.S. Meals and Drug Administration or different relevant authorities; prices associated to the Transactions; adjustments in relevant legal guidelines or rules; the chance that Larkspur or ZyVersa could also be adversely affected by different financial, enterprise, and/or aggressive elements; and different dangers and uncertainties to be recognized within the proxy assertion/prospectus (when out there) referring to the Transactions, together with these beneath “Danger Elements” therein, and in different filings with the SEC made by Larkspur. Furthermore, ZyVersa operates in a really aggressive and quickly altering surroundings. As a result of forward-looking statements are inherently topic to dangers and uncertainties, a few of which can’t be predicted or quantified and a few of that are past Larkspur’s and ZyVersa’s management, you shouldn’t depend on these forward-looking statements as predictions of future occasions. Ahead-looking statements communicate solely as of the date they’re made. Readers are cautioned to not put undue reliance on forward-looking statements, and besides as required by regulation. Larkspur and ZyVersa assume no obligation and don’t intend to replace or revise these forward-looking statements, whether or not because of new data, future occasions, or in any other case. Neither Larkspur nor ZyVersa offers any assurance that both Larkspur or ZyVersa or the mixed firm will obtain its expectations.
SOURCE ZyVersa Therapeutics, Inc.; Larkspur Well being Acquisition Corp.
